March 2023
In this MindMatters, you can: learn more about our five-year, $50-million campaign and how you can play a key role; read an exclusive 50th Anniversary Q&A with our founder; meet the 2022 Lucien Rubinstein Award recipient; and see what’s igniting hope at the 2023 National Conference.
March 2023
In this MindMatters, you can: learn more about our five-year, $50-million campaign and how you can play a key role; read an exclusive 50th Anniversary Q&A with our founder; meet the 2022 Lucien Rubinstein Award recipient; and see what’s igniting hope at the 2023 National Conference.
David Hou Awarded 2022 ABTA Lucien Rubinstein Award for ‘B Cell Vaccine Promotes Anti-Glioma Immunity Through Modulating CD8+ T Cells’
David Hou is awarded for his research on leveraging a B cell vaccine to improve immunotherapy treatment for GBM.
American Brain Tumor Association Announces New Board of Directors Chair, Officers and Member
Meet the newly-appointed ABTA Board Chair and Member and discover what they’re hopeful for in their new roles.
A Targeted Solution in Glioblastoma Treatment
**Sponsored Content**
For adult patients with recurrent GBM, a new clinical trial may offer access to emerging solutions and novel therapies unavailable elsewhere.
Still Pursuing Answers
ABTA Founder Susan Kramer reflects on the last 50 years and her unrelenting pursuit toward finding a cure.
Together, Let’s Meet Hope Head On
Discover how you can play a role in the ABTA’s five-year campaign “Meet Hope Head On.”
Igniting Hope at the National Conference
See what’s igniting hope at the nation’s largest brain tumor conference and how you can get involved.
A Targeted Solution in Glioblastoma Treatment
**Sponsored Content**
For adult patients with recurrent GBM, a new clinical trial may offer access to emerging solutions and novel therapies unavailable elsewhere.
Together, Let’s Meet Hope Head On
Discover how you can play a role in the ABTA’s five-year campaign “Meet Hope Head On.”
David Hou Awarded 2022 ABTA Lucien Rubinstein Award for ‘B Cell Vaccine Promotes Anti-Glioma Immunity Through Modulating CD8+ T Cells’
David Hou is awarded for his research on leveraging a B cell vaccine to improve immunotherapy treatment for GBM.
Igniting Hope at the National Conference
See what’s igniting hope at the nation’s largest brain tumor conference and how you can get involved.
American Brain Tumor Association Announces New Board of Directors Chair, Officers and Member
Meet the newly-appointed ABTA Board Chair and Member and discover what they’re hopeful for in their new roles.
Still Pursuing Answers
ABTA Founder Susan Kramer reflects on the last 50 years and her unrelenting pursuit toward finding a cure.
Calling All Researchers
Take your trailblazing brain tumor research to the next level! The ABTA is now accepting applications for 2023 grant opportunities.
Popular Stories
Research Update: DCVax-L Phase 3 Clinical Trial Data Published for GBM
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
Answering the Top Three CareLine Questions
Vince Rock answers the top questions he receives from patients and caregivers who call the ABTA CareLine.
2023: We’re Better Together
As we welcome 2023, it’s a time to embrace the new year and new ways to get involved and make an impact in the brain tumor community.
Popular Stories
2023: We’re Better Together
As we welcome 2023, it’s a time to embrace the new year and new ways to get involved and make an impact in the brain tumor community.
Answering the Top Three CareLine Questions
Vince Rock answers the top questions he receives from patients and caregivers who call the ABTA CareLine.
Research Update: DCVax-L Phase 3 Clinical Trial Data Published for GBM
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
